Results revealed today at The International Liver Congress 2015, show that in patients with alcohol-induced liver disease (ALD), Baclofen has a positive impact on alcohol consumption and overall measures of liver function and harm. [More]

Alcoholic liver disease (ALD) is one of the leading causes of death worldwide and also in the UK. As its name indicates this disease arises due to consuming excessive amounts of alcohol (80 g/day) over an extended period, normally 10-20 years. [More]

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice. [More]

Relapse is the most painful and expensive feature of drug addiction-even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after treatment. [More]

An estimated 1 in 5 U.S. adults suffer from Gastroesophageal Reflux Disease (GERD), a chronic, often progressive disease that can cause debilitating symptoms and in certain cases lead to esophageal cancer. [More]

Codman & Shurtleff, Inc. (Codman), the global neurological device company, has received U.S. Food and Drug Administration (FDA) approval through a PMA supplement for its MEDSTREAM Programmable Infusion System, an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury. [More]

Scientists at The Scripps Research Institute have developed a powerful new technique for manipulating the building-block molecules of organic chemistry. The technique enables chemists to add new functional molecules to previously hard-to-reach positions on existing compounds-making it easier for them to generate new drugs and other organic chemicals. [More]

Researchers in France and Sweden have discovered how one of the body's own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, are reported in The EMBO Journal. [More]

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011. [More]

A new editorial released this week offers clarity and structure on confusing drug and alcohol addiction terminology for prescribers, users and regulators. "Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?" is published in the Journal of Psychopharmacology, the official journal of the British Association for Psychopharmacology, published by SAGE. [More]

The National Institute on Disability and Rehabilitation Research (NIDRR) of the U.S. Department of Education has awarded researchers at Frazier Rehab Institute and the University of Louisville $2.2 million for five years to establish a Spinal Cord Injury Model System. [More]

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center. [More]

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients. [More]

NewYork-Presbyterian Hospital has established a Pediatric Physical Medicine and Rehabilitation Service, led by Dr. Heakyung Kim. In this role, Dr. Kim will provide specialized care for children with neuromuscular disorders and other special needs at the Hospital's two major centers for pediatric care: Morgan Stanley Children's Hospital at NewYork-Presbyterian Hospital/Columbia University Medical Center and the Komansky Center for Children's Health at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. [More]

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI). [More]

A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and underutilization of intrathecal baclofen (ITB) therapy from Medtronic, Inc. as a treatment option for these patients. [More]

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.